A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase.

In addition to inhibiting the cyclooxygenase (COX)-mediated biosynthesis of prostanoids, various widely used nonsteroidal anti-inflammatory drugs (NSAIDs) enhance endocannabinoid signaling by blocking the anandamide-degrading membrane enzyme fatty acid amide hydrolase (FAAH). The X-ray structure of FAAH in complex with the NSAID carprofen, along with site-directed mutagenesis, enzyme activity assays, and NMR analysis, has revealed the molecular details of this interaction, providing information that may guide the design of dual FAAH-COX inhibitors with superior analgesic efficacy.

[1]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[2]  C. Woolf,et al.  Can we conquer pain? , 2002, Nature Neuroscience.

[3]  Beth A. Fleck,et al.  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor. , 2006, Bioorganic & medicinal chemistry letters.

[4]  B. Cravatt,et al.  Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception , 2009, Journal of Pharmacology and Experimental Therapeutics.

[5]  C. Ledent,et al.  A role for endocannabinoids in indomethacin-induced spinal antinociception. , 2002, European journal of pharmacology.

[6]  A. Saghatelian,et al.  Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  Z. Radi,et al.  Effects of cyclooxygenase inhibition on the gastrointestinal tract. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[8]  Nicola Mongelli,et al.  A general NMR method for rapid, efficient, and reliable biochemical screening. , 2003, Journal of the American Chemical Society.

[9]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[10]  C. Fowler,et al.  Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors , 2005, British journal of pharmacology.

[11]  Raymond C Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[12]  M. Malkowski,et al.  The productive conformation of arachidonic acid bound to prostaglandin synthase. , 2000, Science.

[13]  Raymond C Stevens,et al.  Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. , 2010, Journal of molecular biology.

[14]  L. Marnett,et al.  Arachidonic Acid Oxygenation by COX-1 and COX-2 , 1999, The Journal of Biological Chemistry.

[15]  D. Boger,et al.  Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain , 2009, Journal of Pharmacology and Experimental Therapeutics.

[16]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[17]  D. Boger,et al.  The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). , 2011, Bioorganic & medicinal chemistry letters.

[18]  Sandy J. Wilson,et al.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006 .

[19]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[20]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[21]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[22]  C. Fowler,et al.  Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen , 2001, British journal of pharmacology.

[23]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[24]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[25]  A. Lichtman,et al.  The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1 , 2009, British journal of pharmacology.

[26]  S. Chaplan,et al.  Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse , 2008, Neuroscience.

[27]  B. Cravatt,et al.  Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. , 2003, Current opinion in chemical biology.

[28]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[29]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[30]  S. Johnston,et al.  Use of carprofen for the treatment of pain and inflammation in dogs. , 1997, Journal of the American Veterinary Medical Association.

[31]  A. Hohmann,et al.  Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism , 2010, Nature Neuroscience.

[32]  Zhihua Ma,et al.  Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH) , 2011, Proceedings of the National Academy of Sciences.

[33]  G. Nuki.  Non-steroidal analgesic and anti-inflammatory agents. , 1983, British medical journal.

[34]  Lawrence J. Marnett,et al.  Structural insights into the stereochemistry of the cyclooxygenase reaction , 2000, Nature.

[35]  C. Fowler,et al.  Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. , 2007, European journal of pharmacology.

[36]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[38]  Sandy J. Wilson,et al.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006, British journal of pharmacology.

[39]  Raymond C Stevens,et al.  Structure-guided inhibitor design for human FAAH by interspecies active site conversion , 2008, Proceedings of the National Academy of Sciences.

[40]  R. Bertorelli,et al.  Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. , 2012, Pharmacological research.

[41]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[42]  D. Boger,et al.  Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics. , 2011, Journal of medicinal chemistry.

[43]  D. Boger,et al.  Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase. , 2011, Journal of the American Chemical Society.

[44]  Raymond C Stevens,et al.  Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. , 2009, Journal of the American Chemical Society.